A study was undertaken to determine the time constants of elimination and effect compartment equilibration of suxamethonium and for the slope exponent of the Hill equation. Twelve patients were anaesthetized with thiopentone, fentanyl, and isoflurane in nitrous oxide and oxygen. After allowing conditions to become stable, they were administered three small doses of suxamethonium by rapid intravenous injection. The responses to supramaximal stimulation of the ulnar nerve were recorded by EMG in one and by accelerometry in eleven subjects. Because of failure to recover to control conditions, one subject was deleted from analysis. The recorded drug effect was used in a non-linear curve fitting technique to derive estimates of the pharmacokinetic and pharmacodynamic parameters. The plasma concentration of suxamethonium was adequately represented by a single compartment model. The mean half-life of elimination was 47s with a 95% confidence interval of 24 to 70 s; that of effect compartment equilibration, 211s with a 95% confidence range of 139 to 282s. The average slope exponent was 6.4 and its 95% confidence range was 4.6 to 8.2. The data from the first two doses were used to predict the time taken for the third dose to recover 50%. The predictions showed a mean bias of <1% (NS) and a mean error of 21%, with a confidence interval of 5 to 37%. In only two out of eleven subjects was the prediction error greater than 30%.
Suxamethonium has enjoyed clinical use for nearly 50 years, yet its pharmacokinetics (PK) and its pharmacodynamics (PD) are virtually unknown in man 1 . There are several reasons for this surprising lack of information on a commonly used drug. First, there is the difficulty in preventing hydrolysis of the drug in blood samples. Second was a lack of reliable assay until relatively recently 2 and it may be the fact that the drug is generic that has restricted the availability of funding for its investigation. Having developed a technique for deriving PK rate constants and the slope exponent of the concentration-effect curve from effect data alone 3 , we applied this technique to data from eleven consenting patients to derive the rate constants of elimination and of equilibration of the effect compartment as well as the Hill exponent for suxamethonium.
METHODS
The study was approved by the Research Ethics Committee of the Eastern Sydney Area Health Service. Twelve ASA status 1 or 2 patients undergoing spinal surgery were investigated. In one patient recovery failed to meet the necessary criteria set out in the document published by the international consensus conference on good clinical research practice in PD studies of neuromuscular blocking agents 4 . This patient was not included in further analysis. After preoxygenation, anaesthesia was induced with fentanyl and thiopentone and maintained with nitrous oxide, oxygen and isoflurane 1 to 1.5% inhaled concentration. Intubation was facilitated by the use of topical lignocaine. End-tidal carbon dioxide was maintained between 35 and 40 mmHg (4.9-5.6 kPa) with constant volume ventilation. Neuromuscular transmission was measured with a "TOFGuard" accelerometer (Organon Teknika) in ten subjects and because of a temporary problem with the accelerometer, with a "Relaxograph" EMG recorder (Datex) in one, using a train-of-four pattern at 15 s intervals with the TOFGuard and 20 s intervals with the Relaxograph. The patient whose response was recorded by electromyography was patient 4 in Tables  1 and 2 . The train-of-four pattern was chosen to detect possible changes from phase 1 to phase 2 block during the studies. The recording of neuromuscular transmission was allowed to stabilize for at least 20 minutes at constant isoflurane concentration. A small, 15 to 30 mg dose of suxamethonium was then administered into a rapidly flowing intravenous infusion and its effect was recorded. When recovery was greater than 75%, a second and then a third dose, chosen at random, was administered. Small relaxant doses were chosen in order to avoid sudden onset of complete blockade and prolonged periods of zero response to nerve stimulation. Both core and peripheral temperatures were monitored with thermistors and the hand from which the recording was made was warmed with a 40 watt incandescent light globe, placed about 30 cm from the hand. The conditions of the studies complied with the recommendations of the international consensus conference on neuromuscular research 5 .
The recording of the effect of the suxamethonium was then transferred to the spreadsheet of Mk model (V. 5.0, Biosoft, Cambridge, U.K.) 5 , a pharmacokinetic modelling program. The method of fitting the data to an effect compartment model has been described elsewhere 3 and is briefly described again in Appendix 1. The data was fitted using single and twocompartment models, leading to two and three exponential models for the effect compartment. The Hill equation was used to relate the effect compartment concentration to effect. The data for each subject was fitted initially for the first two doses and then for all three doses to compare goodness-of-fit. The data were not weighted. The structural parameters of the two-dose fit were also used to predict the time to 50% recovery following the third dose. This was compared to the actual recovery time to give a simple measure of the predictive value of the method.
The goodness-of-fit was estimated by the log likeli- hood, a statistic considered by Holford 5 superior to the regression coefficient for use in extended least squares regression. Comparison of the various models was made by means of the Schwarz criterion 6 , which takes into account the number of parameters used (see Appendix 2) .
RESULTS
Of the twelve patients initially entered into the study, recovery failed to reach greater than 80% of the control value in one subject, although the TOF ratio returned to 1. This subject was not analysed further. In the remaining eleven, recovery was greater than 80% in all, with TOFR >0.8 and a stable state at the end of the study. Four were male and seven female and their mean age was 37 years (±12 years, SD). The average weight was 69±10 kg. The first dose varied from 15 to 30 mg (0.24 to 0.37 mg.kg -1 ). Subsequent doses varied from 5 to 20 mg (0.07 to 0.32 mg.kg -1 ).
In all subjects, after each of the three doses, including the first dose, there was reduction of the TOFR to about 0.4 or 0.5. This was not apparent during onset of the blockade but was observable until T1 recovered to >0.5 of control, when the TOFR returned to about 1 (Figure 1 ). There was no other evidence of phase 2 block, and this tendency was the same for all three doses, without greater reduction of the TOFR after the third dose than after the first.
The Preferred Model
For each subject, first the initial two doses and then all three doses were fitted to single and two compartment plasma models (2 and 3 exponentials, respectively, for the effect compartment concentration). Using data from the first two doses the curve fits for all subjects converged, using a one-compartment model, as did the data for ten of the eleven subjects when using a two-compartment model. In one subject the response data could not be fitted to the two- The part of the printed output of the TOFGuard accelerometer, during one of the studies, to show the reduction of TOFR usually seen during early recovery, as discussed in the text. The top lines are skin temperature, ranging from 35 down to 32°C. The actual temperature was mostly just over 34°C. "TOF" denotes the type of stimulation with the adjacent number, the magnitude of the first response as a percentage of control. Where the magnitude of the fourth response (again as % of control) is not displayed, the asterisks denote the number of responses recorded in the train. The fourth column is the magnitude of the fourth response as a percentage of the first, the train-of-four ratio or TOFR. The graph shows each individual response with the time from start of recording below it. The chart shows recovery from the first and the responses to the second and third doses. compartment model. Using data from the first two doses and a two-compartment model, the Schwarz criterion indicated a significantly improved fit in only one subject. The mean log-likelihood and Schwarz criterion (±SD) for the one-compartment model was 69±33 and 59±33 respectively, and for the twocompartment model they were 70±36 and 56±35, demonstrating no significant gain by increasing the complexity of the model.
Using all three doses for fitting for the PK and PD parameters, the two-compartment fit failed to converge for the same patient as was the case using two doses only. Of the remaining ten the Schwarz criterion improved significantly in four compared to the one-compartment fits. The average values for the two measures of fit were 82±44 and 71±43 for the single compartment model and 94±44 and 79±44 for the two-compartment. These values, using data from three doses, are significant improvements over the fits for the first two doses only and therefore represent a better set of PK and PD parameters. Although the use of a two-compartment model was justified by the improvement in the Schwarz criterion, in some of the subjects the improvement was not great and the model could only be fitted to ten of the eleven patients.
PK and PD Parameters
In view of the above, the PK and PD parameters were derived from the one-compartment model. The values of the dose-dependent parameter of the model (A in Eq. 7 of Appendix 1) are in units of the individual patient's EC 50 's (concentration for 50% effect) and cannot be determined in absolute units by this method. This parameter was normalized to a dose of 1 mg.kg -1 . All the estimated PK and PD parameters are summarized in Table 1 . Using all three doses for the fits, the mean rate constant of elimination was 1.47±0.94 minute -1 , corresponding to a mean half-life of 47±39 s and the rate constant of equilibration for the effect compartment was 0.27±0.15 minute -1 , a half-life of 211±121s. The 95% confidence intervals for the half-lives were 24-70 s and 139-282 s respectively. The exponent of the Hill function, γ (see Appendix 1), was 6.4±2.7. When only two doses were fitted, in order to permit a prediction for the duration of the effect of the third dose, the values for α and k eo , were 1.45±0.92 minute -1 (halflife of 43±32 s) and 0.22±0.11 minute -1 (half-life of 244±157) and γ was 7.9±3.3.
Prediction of Duration of Action
The time taken to 50% recovery following the administration of the third dose was recorded and compared with the predictions made from the PK and PD parameters calculated from the first two doses. This was done using both the one-and the twocompartment models. The predictions based on the one-compartment model were slightly better, with a mean error (±SD) of 21±25%, 95% confidence interval 4.5 to 38% (N=11), compared to 26±33% and 2.5 to 49% for the two-compartment model (N=10). Only two subjects had errors greater than 30%, but these were 63 and 69% for the onecompartment and 63 and 97% for the twocompartment models. The bias was -0.2±1.1% and -0.4±1.3% for the two models respectively. Neither value was statistically significant.
DISCUSSION
The assay of suxamethonium in plasma is difficult 2 , which may account for the paucity of PK and PD data in the literature. We have found only one reference to a study of the PK of suxamethonium in man 7 , which reported elimination half-lives of 16.6 and 11.7 s for 1 and 2 mg.kg -1 doses, respectively. There have been several papers based on an assumption of linear, not sigmoid, relation between log dose and effect 8, 9 , and relating effect to the log of the plasma concentration. These models cannot predict recovery to any point other than that used to determine a single "duration of action" in the calibration studies. Additional difficulty would be introduced if this point were on the non-linear portion of the dose-response curve. Our model analyses the effect data in terms of an elimination rate constant for plasma and an equilibration rate constant for the effect compartment, which is more in keeping with present day pharmacokinetic modelling practice. The dose response relation is modelled as sigmoid, using the Hill equation and the effect compartment concentration.
It can be seem from inspection of equation 4 in Appendix 1, that with suitable adjustment in the value of "A", the two rate constants are interchangeable. Our models were so constrained that k eo was always the lesser of the two rate constants.
In our patients, a slight fade of the TOF ratio was always seen during early recovery while the blockade was greater than 50%. Although often neglected, this is a common finding and not considered to be evidence of a phase II block 10 . This fade of the TOFR did not persist and during the latter phases of recovery, T 1 was about the same size as T 4 , until recovery was complete when enhancement of T 4 was often seen as was the case before drug administra-tion. We therefore conclude that no observable phase II block was present during these studies.
The choice of preferred model is subjective in some ways. It is usual to find that data from some subjects is better fitted by one model and from others, by another. In general, the addition of extra "compartments" and parameters will improve the fit but each additional parameter, however, introduces added complication and added variability into the model. It is therefore best to use the simplest model which will adequately describe the data. In this case, this is clearly the single compartment plasma model. From inspection of the middle panels in Figure 2 it is evident that only in two subjects did the addition of a second compartment to the plasma model significantly change the effect compartment concentration.
Our method is able to describe the concentration parameter (A) only in terms of the EC 50 of the individual subject. It is, however, able to provide rate constants for elimination (and for distribution, if a two-compartment model is used) and effect compartment equilibration without the need for drug assays. The area under the concentration-time curve (AUC) is in units of EC 50 times time, and not mass per unit volume times time. Hence clearance (which is dose/AUC) is also in these relative terms, but this is sufficient to derive a hypothetic infusion rate for 50% block 11 . From this it is simple to derive a rate for any other degree of blockade. Although the administration of suxamethonium by infusion is unlikely to come back into vogue, the method can be applied to any other relaxant provided sufficient data has been gathered to provide for curve fitting in the individual patient.
We subjected our method to a test of validity by taking the data from the first two doses and predicting the time to 50% recovery from the third dose ( Figure 3) . Considering that most studies of relaxant kinetics reveal 95% confidence intervals for individual subjects over a threefold or greater range, the fact that we were able to predict the duration of the effect of the third dose without significant bias and with a mean error of only 21% shows that this method has a potential for predicting individual responses to relaxants, with greater accuracy than can be achieved from population data. This holds out promise of a worthwhile clinical application in determining dosage to individual patients. The method can also be applied to drugs other than neuromuscular blockers, provided effect can be measured and maximal effect defined.
APPENDIX 1
The plasma concentration of a drug following instantaneous bolus intravenous administration is usually described by the sum of a series of exponentials, each representing a hypothetical distribution compartment each with its own equilibration rate constant, and a rate constant for the elimination of the drug.
where C p is the concentration in the plasma or central compartment at time t, C i is the concentration at time 0 in the i'th compartment, and λ i is the rate constant of equilibration of the compartment or an elimination rate constant. In terms more familiar to anaesthetists, a one-compartment model where the drug is confined to the central compartment and eliminated from there (i=1) would be
where A is the concentration intercept at time 0, and α the elimination rate constant. For a situation where the drug equilibrates with a peripheral or tissue compartment and is eliminated from the plasma:
Now A+B is the 0 time intercept and α the equilibration rate constant of the peripheral compartment and β. the rate constant of elimination.
It is obvious that the time course of the plasma concentration (C p ) cannot be equated with the effect. After all, when the C p is maximal, at time 0, effect is 0. Only some considerable time later, when C p has fallen significantly, is maximal effect reached. To account for this, the effect compartment (sometimes called biophase) is defined, so that the concentration in this compartment (C e ) is such that it accounts for the observed effect 12 . To make the mathematics possible, this compartment is defined as so small that drug loss into the compartment does not affect the plasma concentration. The concentration in this compartment relates to the plasma concentration by a rate constant, usually called k eo . For a single compartment plasma model (equation 2) the effect compartment concentration is:
Corresponding increasingly complex equations can also be set up for multicompartment models.
The relation between drug concentration and the effect of relaxants is sigmoid and is usually represented by the Hill equation:
γ Unless plasma concentrations are measured during recording of effect, the EC 50 is unknown and if equation 5 were used for curve fitting, an infinite number of solutions for A would be possible, with corresponding EC 50 's. Therefore to make it possible to obtain a solution for equation 4, the EC 50 is made the unit of drug concentration so that equation 5 becomes:
into which the right hand terms of equation 4 are substituted for curve fitting: 
[ (α -k eo )
The curve-fitting algorithm then finds the optimal solution for the unknowns, A, α, K eo and γ to fit the recorded effect.
APPENDIX 2
The correlation coefficient of a linear regression is strictly a measure of the closeness of linear relation-ship between two variables 13 . Holford 5 considers it meaningless for non-linear curve fitting which uses weighted or extended least squares regression. He uses two other measures, the log likelihood, which indicates how well the parameter values in the model describe the data:
where O i is the objective function for each observation which is minimized by the search process of the extended least squares regression and n the number of observations. To compare different models used to fit the same data he uses the Schwarz criterion: k SC = LL -.ln(n) (9) 2 where k is the number of structural and variance parameters used and n the number of observations.
